Advertise with Pune MediaAdvertise with Pune MediaAdvertise with Pune MediaAdvertise with Pune Media

Top 5 This Week

Advertise with Pune MediaAdvertise with Pune MediaAdvertise with Pune MediaAdvertise with Pune Media

Related Posts

Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)

Editorial Disclosure: This article is curated from reporting by the original publisher credited below. It was selected and published automatically under the Pune.Media Editorial Policy and is not original Pune.Media reporting.

Original Coverage & Source Attribution: seekingalpha.com

PhonlamaiPhoto/iStock via Getty Images

Editas Medicine (EDIT) traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company’s gene-editing therapy EDIT-401, and Wells Fargo upgraded the biotech to Overweight from Equal Weight in reaction.

In a statement, Cambridge, Massachusetts-based Editas (

Popular Articles